MK771

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 525654

CAS#: 66537-55-1

Description: MK771 is a therapeutic agent and an analog of the Thyrotropin Releasing Hormone (TRH). TRH and its analogs may be useful in combating some of the withdrawal symptoms in opiate-dependent subjects.

Chemical Structure

img
MK771
CAS# 66537-55-1
Instruction

Theoretical Analysis

MedKoo Cat#: 525654
Name: MK771
CAS#: 66537-55-1
Chemical Formula: C16H22N6O4S
Exact Mass: 394.14
Molecular Weight: 394.449
Elemental Analysis: C, 48.72; H, 5.62; N, 21.31; O, 16.22; S, 8.13

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: MK-771; MK 771; MK771

IUPAC/Chemical Name: (S)-3-((S)-3-(1H-imidazol-4-yl)-2-((S)-6-oxopiperidine-2-carboxamido)propanoyl)thiazolidine-4-carboxamide

InChi Key: OGUDACTYCTVDNZ-SDDRHHMPSA-N

InChi Code: InChI=1S/C16H22N6O4S/c17-14(24)12-6-27-8-22(12)16(26)11(4-9-5-18-7-19-9)21-15(25)10-2-1-3-13(23)20-10/h5,7,10-12H,1-4,6,8H2,(H2,17,24)(H,18,19)(H,20,23)(H,21,25)/t10-,11-,12+/m0/s1

SMILES Code: O=C([C@H](CCC1)NC1=O)N[C@@H](CC2=CNC=N2)C(N3CSC[C@@H]3C(N)=O)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 394.45 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Hutson PH, Semark JE, Middlemiss DN. The TRH analogue MK-771, increases acetylcholine release in hippocampus but not striatum of the conscious rat. Neurosci Lett. 1990 Aug 14;116(1-2):149-55. PubMed PMID: 2124336.
2: Sills MA, Jacobowitz DM. Chronic administration of desipramine or nialamide decreases wet-dog shakes in rats produced by the TRH-analog MK-771. Brain Res. 1987 Jan 13;401(1):195-9. PubMed PMID: 3101979.
3: Horita A, Carino MA, Lai H. Preliminary studies on the effects of a TRH analog, MK-771, in an animal model of Alzheimer's disease. Proc West Pharmacol Soc. 1987;30:57-8. PubMed PMID: 3114755.
4: Simasko SM, Horita A. Treatment of rats with the TRH analog MK-771. Down-regulation of TRH receptors and behavioral tolerance. Neuropharmacology. 1985 Feb;24(2):157-65. PubMed PMID: 2986033.
5: Nielsen JA, Moore KE. Thyrotropin-releasing hormone and its analog MK-771 increase the cerebroventricular perfusate content of dihydroxyphenylacetic acid. J Neurochem. 1984 Aug;43(2):593-6. PubMed PMID: 6429282.
6: Brady LS, Valentine JO, Barrett JE. Effects of thyrotropin-releasing hormone (TRH) and a TRH analogue, MK-771, on punished responding of squirrel monkeys. Psychopharmacology (Berl). 1984;83(2):151-4. PubMed PMID: 6431464.
7: Barrett JE. Effects of thyrotropin-releasing hormone (TRH) and MK-771 on schedule-controlled behavior of squirrel monkeys, rabbits and pigeons. Peptides. 1983 Mar-Apr;4(2):177-81. PubMed PMID: 6413956.
8: Funatsu K, Teshima S, Inanaga K. Binding of TRH, DN-1417 and MK-771 to TRH receptors in the rat brain. Relationship to their central actions. Kurume Med J. 1983;30 Suppl:S45-50. PubMed PMID: 6090771.
9: Rastogi RB, Singhal RL. MK-771 enhances the turnover of norepinephrine in brain. Res Commun Chem Pathol Pharmacol. 1981 Jul;33(1):187-90. PubMed PMID: 6115460.
10: Horita A, Carino MA. A comparison of the pharmacological properties of TRH and MK-771. Proc West Pharmacol Soc. 1981;24:347-8. PubMed PMID: 6789338.
11: Horita A, Carino MA, Zabawska J, Lai H. TRH analog MK-771 reverses neurochemical and learning deficits in medial septal-lesioned rats. Peptides. 1989 Jan-Feb;10(1):121-4. PubMed PMID: 2501767.
12: Sills MA, Jacobowitz DM. Propranolol and methylatropine antagonize the cardiovascular effects produced by microinjection of the TRH analog MK-771 into the preoptic suprachiasmatic nucleus. Peptides. 1988 Jul-Aug;9(4):893-8. PubMed PMID: 3147455.
13: Sills MA, Mellow AM, Sunderland T, Jacobowitz DM. Central muscarinic cholinergic antagonists block wet-dog shakes produced by the TRH analog MK-771 in the rat. Brain Res. 1988 Jun 21;453(1-2):385-8. PubMed PMID: 3135919.
14: Bhargava HN, Matwyshyn GA. Comparative effects of thyrotropin releasing hormone, MK-771 and DN-1417 on morphine abstinence syndrome. Psychopharmacology (Berl). 1985;87(2):141-6. PubMed PMID: 2996045.
15: Brady LS, Barrett JE. Effects of thyrotropin-releasing hormone (TRH) and MK-771 on behavior of squirrel monkeys controlled by noxious stimuli. Peptides. 1984 Jul-Aug;5(4):783-7. PubMed PMID: 6436798.
16: Yamada K, Demarest KT, Moore KE. Effects of behaviorally active doses of thyrotropin-releasing hormone and its analog MK-771 on dopaminergic neuronal systems in the brain of the rat. Neuropharmacology. 1984 Jul;23(7A):735-9. PubMed PMID: 6433220.
17: Vickers S, Duncan CA, Arison BH, Ramjit HG, Rosegay A, Nutt RF, Veber DF. Metabolism of the TRH analog L-pyro-2-aminoadipyl-L-histidyl-[3H]-L-thiazolidine-4-carboxamide (MK-771) in gut and brain tissue of rats: the implications for its bioavailability. Drug Metab Dispos. 1983 Mar-Apr;11(2):147-51. PubMed PMID: 6133720.
18: Yarbrough GG, Faison EP, Antolik EK. MK-771 antagonizes the enhanced response to apomorphine in rats treated chronically with haloperidol - implications for tardive dyskinesia. Neurosci Lett. 1982 Dec 31;34(3):321-3. PubMed PMID: 6819493.
19: Santori EM, Schmidt DE, Kalivas PW, Horita A. Failure of muscarinic blockade to antagonize analepsis induced by thyrotropin-releasing hormone and MK-771 in the rat. Psychopharmacology (Berl). 1981;74(1):13-6. PubMed PMID: 6115440.
20: Lotti VJ, Yarbrough GG, Clineschmidt BV. Investigations on the interaction of thyrotropin-releasing hormone (TRH) and MK-771 with central noradrenergic mechanisms. Psychopharmacology (Berl). 1980;70(2):145-8. PubMed PMID: 6776573.